Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Lead-In Dosing of Sotorasib Plus Pembrolizumab Shows Promising Safety for KRAS G12C+ NSCLC

August 7th 2022

A lead-in dosing strategy for the combination of sotorasib in combination with either pembrolizumab or atezolizumab showed promising efficacy and relatively low rates of hepatotoxicity in patients with KRAS G12C–positive non–small cell lung cancer.

Sitravatinib/Tislelizumab Combo Induces Antitumor Activity in PD-L1+ Advanced NSCLC

August 7th 2022

Sitravatinib in combination with tislelizumab demonstrated a confirmed investigator-assessed overall response rate of 30.4% in patients with PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

GDC-6036 Monotherapy Elicits Promising Responses in KRAS G12C–Mutant NSCLC

August 7th 2022

GDC-6036, a novel KRAS G12C inhibitor, produced encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated NSCLC, according to data from a phase 1a trial.

Sintilimab Elicits Similar Efficacy, Safety Vs Pembrolizumab in Advanced NSCLC

August 7th 2022

Sintilimab, both as a single agent and in combination with chemotherapy, generated comparable efficacy and safety vs pembrolizumab in patients with untreated metastatic non–small cell lung cancer.

Subtyping MET Exon 14 Skipping Mutations Provides Insight Into Distinct Microenvironments in NSCLC

August 7th 2022

Four distinct subgroups, each associated with distinctive signaling pathways, microenvironments, and clinical-pathologic futures, were discovered in a population of patients with MET exon 14 skipping non–small cell lung cancer.

Neoadjuvant Chemoimmunotherapy Supported by Differences in pCR and non-pCR Responders in Stage IIIA NSCLC

August 7th 2022

The use of a platinum-based chemotherapy and anti–PD-1 regimen was supported by differences in upregulated antigen processing, T-cell receptor coexpression, and lymphocyte infiltration pathways in patients with or without pathologic complete responses who had stage IIIA resectable non–small cell lung cancer.

Consolidation Sugemalimab Provides Sustained PFS Benefit in Unresectable Stage III NSCLC

August 7th 2022

Sugemalimab appeared to be safe and effective when used as consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) who did not have disease progression following concurrent chemoradiation or sequential chemoradiation.

Larotrectinib Demonstrates Favorable Long-Term Responses in NTRK Fusion–Positive Lung Cancer

August 6th 2022

Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.

Ociperlimab Plus Tislelizumab Demonstrates Antitumor Activity in PD-L1+ NSCLC

August 6th 2022

Ociperlimab, an anti-TIGIT monoclonal antibody, plus the anti–PD-L1 monoclonal antibody tislelizumab induced promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer, according to data from the dose-expansion cohort of the AdvanTIG-105 trial.

Tremelimumab/Durvalumab Plus Chemotherapy Improves OS in PD-L1–Negative NSCLC

August 6th 2022

The addition of tremelimumab to durvalumab and chemotherapy improved clinical benefit and survival benefit vs. chemotherapy alone in patients with PD-L1–negative metastatic non–small cell lung cancer.

Tislelizumab Maintains OS Benefit Vs Docetaxel in Previously Treated NSCLC

August 6th 2022

Second- or third-line tislelizumab continued to display an overall survival benefit vs docetaxel in patients with non–small cell lung cancer.

Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC

August 6th 2022

Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.

Sacituzumab Govitecan Under Further Exploration in Pretreated Metastatic NSCLC

August 6th 2022

The antibody-drug conjugate sacituzumab govitecan will be evaluated vs single-agent docetaxel during the phase 3 EVOKE-01 trial in patients with metastatic non–small cell lung cancer.

Osimertinib/Savolitinib Combo Looks to Overcome Acquired Resistance in EGFR-Mutant NSCLC

August 5th 2022

Acquired resistance because of genetic alterations in the MET receptor has limited the efficacy of the EGFR inhibitor osimertinib in patients with non–small cell lung cancer. Investigators have sought to circumvent this barrier through targeting MET protein activity with the addition of the novel MET TKI, savolitinib.

CheckMate 9LA: Dual IO Therapy With Chemotherapy in Advanced NSCLC

August 5th 2022

Shared insight on the CheckMate 9LA trial, which combined dual IO therapy with chemotherapy in the setting of advanced non–small cell lung cancer.

Dual IO Therapy in Advanced NSCLC: Long-Term Followup From CheckMate 227

August 5th 2022

Expert perspectives on the CheckMate 227 clinical trial, which combined ipilimumab and nivolumab IO therapy in patients with advanced NSCLC.

Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

August 4th 2022

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.

Sintilimab Combo Extends PFS in Previously Treated EGFR-Mutated NSCLC

August 3rd 2022

Sintilimab in combination with a bevacizumab biosimilar plus pemetrexed and cisplatin induced a progression-free survival benefit of 2.6 months compared with chemotherapy alone for patients with EGFR-mutated, locally advanced or metastatic non–small cell lung cancer, according to interim findings from the ongoing phase 3 ORIENT-31 trial.

Single-Agent Liposomal Irinotecan Fails to Meet OS End Point in Second-Line Treatment of SCLC

August 3rd 2022

Liposomal irinotecan did not provide an overall survival benefit compared with topotecan as a second-line treatment for patients with small cell lung cancer who progressed on or after first-line platinum-based chemotherapy.

Eftilagimod Alpha/Pembrolizumab Combo Elicits Encouraging Survival Benefits in Anti–PD-1/PD-L1 Refractory NSCLC

August 2nd 2022

Eftilagimod alpha plus pembrolizumab demonstrated promising benefits in overall survival and progression-free survival as a second-line treatment in patients with non–small cell lung cancer who progressed on anti–PD-1/anti–PD-L1 therapy.